Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$76.4M
Filings
334
Firms Hired
7
Active Period
2002–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: HR 1843
Stop STALLING Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1095
Stop STALLING Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1095
Preserve Access to Affordable Generics and Biosimilars Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1096
Preserve Access to Affordable Generics and Biosimilars Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1096
Interagency Patent Coordination and Improvement Act of 2025
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1097
Interagency Patent Coordination and Improvement Act of 2025
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1097
Skinny Labels, Big Savings Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 43
Skinny Labels, Big Savings Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 43
Trump Tariff Transparency Act
2026 · third_quarter · Firm: TEVA PHARMACEUTICALS USA INC
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Client expense: $310,000 · Firm income: —
Matched citations: H.R.6888
Tariff Transparency Act of 2025
2026 · third_quarter · Firm: TEVA PHARMACEUTICALS USA INC
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Client expense: $310,000 · Firm income: —
Matched citations: S.959
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
2026 · third_quarter · Firm: TEVA PHARMACEUTICALS USA INC
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Client expense: $310,000 · Firm income: —
Matched citations: S.J.Res.37
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: HR 1843
Stop STALLING Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1095
Stop STALLING Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1095
Preserve Access to Affordable Generics and Biosimilars Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1096
Preserve Access to Affordable Generics and Biosimilars Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1096
Interagency Patent Coordination and Improvement Act of 2025
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1097
Interagency Patent Coordination and Improvement Act of 2025
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 1097
Skinny Labels, Big Savings Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 43
Skinny Labels, Big Savings Act
2026 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform; Schizophrenia treatment awareness.
Client expense: — · Firm income: $60,000
Matched citations: S 43
Trump Tariff Transparency Act
2026 · second_quarter · Firm: TEVA PHARMACEUTICALS USA INC
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Client expense: $380,000 · Firm income: —
Matched citations: H.R.6888
Tariff Transparency Act of 2025
2026 · second_quarter · Firm: TEVA PHARMACEUTICALS USA INC
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).
Client expense: $380,000 · Firm income: —
Matched citations: S.959
Source: Senate LDA